Home » Health & Medicine, Hospitality, News & Current Affairs, Pharmaceuticals & Biotech, World » Global Attention-Deficit Hyperactivity Disorder Therapeutics Market Expected to Account US$ 25,054.4 Mn by 2024 – PMR
“Attention-Deficit-Hyperactivity-Disorder – ADHD-Therapeutics – Market”
The global ADHD therapeutics market was valued at US$ 14 Bn in 2014, and is expected to increase to US$ 25 Bn by 2024 end, at a CAGR of 6.2% during the forecast period.

According to a new report published by Persistence Market Research, “Global Market Study on Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics: Industry Analysis and Forecast 2015-2024”, the global market valued US$ 14 Bn at the end of 2014 and is projected to reach the value of US$ 25 Bn at the end of 2024, expanding at a steady 6.2% CAGR through the forecast period. The expected market trend is owing to the rising ADHD drug usage among adults and novel drug development.

Major drivers in the global ADHD therapeutics market include growing prevalence due to low threshold of diagnostic criteria, rising awareness in regards to ADHD, and the shift from ICD-10 to DSM-IV. Cultural differences towards ADHD, development of novel drugs, and increasing usage among adults are other major current market trends driving the global ADHD therapeutics market. Furthermore, adoption of alternative treatments and rising incidences of drug abuse are major factors restraining the global market. Also, launch of cheaper drugs in its generic form post-patent expiry by companies to increase market share is expected to hamper revenue generation for the major players in the global market.

By drug type, the global ADHD market is segmented as stimulants and non-stimulants. Stimulants is further sub-segmented into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate. The non-stimulant segment is further sub-segmented into Automoxetine, Bupropion, Guanfacine, and Clonidine. Lisdexamfetamine Dimesylate sub-segment is projected to expand at a staggering CAGR of 15.6% in terms of value through the forecast period to reach the value of US$ 5.68 Bn at the end of 2024. Stimulants are projected to be the most preferred drug type in regards to physicians and patients both, globally. Amphetamine is anticipated to be the second-most popular drug type sub-segment, projected to expand at a CAGR of 4.2% through the forecast period.

 Download Report Table of Content, Figures, and Tables: http://www.persistencemarketresearch.com/market-research/attention-deficit-hyperactivity-disorder-therapeutics-market/toc

In terms of distribution channel, the market is segmented as specialty clinics, hospital pharmacies, retail pharmacies, and e-commerce. Retail pharmacies is the leading segment, accounting for 44% of the revenue share in 2015 and is projected to maintain its dominating trend through the forecast period. In terms of age group, the global ADHD therapeutics market is segmented as pediatric and adolescent, and adults. Adults segment is dominating the global market with 50.4% share in terms of revenue at the end of 2015 and is projected to continue with the market trend through the forecast period.

 Request Sample Report: http://www.persistencemarketresearch.com/samples/4222

The global ADHD therapeutics market is segmented by region into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America is the leading region, estimate to account for the maximum value share at the end of 2016. Europe and North America are anticipated to account for four-fifths revenue share in the global market, collectively, at the end of 2024. North America is expected to expand at a CAGR of 5.9% through 2015-2024.

 Browse Full Report Overview: http://www.persistencemarketresearch.com/market-research/attention-deficit-hyperactivity-disorder-therapeutics-market.asp

Major players in the global ADHD therapeutics market include Eli Lilly and Company, Noven Pharmaceuticals, Inc., Purdue Pharma L.P., Amedra Pharmaceuticals LLC., Novartis Pharmaceuticals Corporation, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Celltech Group Ltd., and Shire. Companies are investing in research and development for innovative products and to provide cost-effective treatment to increase their market share and strengthen market position globally.

Media Contact
Company Name: Persistence Market Research
Contact Person: Rahul Singh
Email: rahul@persistencemarketresearch.com
Phone: 6465687751
Address:305 Broadway, 7th Floor
City: New York
State: NY
Country: United States
Website: http://www.persistencemarketresearch.com/market-research/attention-deficit-hyperactivity-disorder-therapeutics-market.asp

Comments are closed.